Search - tctmd.com

Displaying 1 - 20 of 56

Sort: Relevancy | Date

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

L.A. McKeown

December 23, 2024

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

Caitlin E. Cox

December 28, 2023

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Shelley Wood

June 05, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Advertisement

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

FDA Approves Triple Therapy Polypill for High Blood Pressure

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

June 2024 Dispatch for the CV Team

Biologic Winrevair Wins FDA Approval for Treatment of PAH

Bempedoic Acid Gains CV Risk Reduction Indication

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

FDA Grants MACE Reduction Indication for Semaglutide

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

TCTMD’s Top 10 Most Popular Stories for December 2023

Top Endovascular News of 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Colchicine for Decreasing CV Events

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Most Patient-Reported Outcome Measures in CVD Fall Short

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content